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Abstract 
Objective: To compare non-Hodgkin lymphoma (NHL) incidence rates in adults who 
started antiretroviral therapy (ART) across the Asia-Pacific, South Africa, Europe, 
Latin, and North America. 
Methods: We included cohort data of adults living with HIV who started ART after 
1995 within the framework of the International epidemiology Databases to Evaluate 
AIDS (IeDEA) and the Collaboration of Observational HIV Epidemiological Research 
in Europe (COHERE). We used flexible parametric survival models to compare 
regional NHL rates at 2 years after ART start and to identify risk factors for NHL.  
Results: We included 210,898 adults with 1.1 million person-years (pys) of follow-up 
and 1,552 incident NHL cases (raw overall incidence rate 142/100,000 pys). After 
adjusting for age at ART start, first-line ART regimen, calendar period of ART start, 
and especially current CD4 cell count, NHL rates were similar across regions for most 
population groups. However, South African women remained at increased risk of 
developing NHL compared with their European counterparts (adjusted hazard ratio 
[aHR] 1.79, 95% CI 1.19-2.70). In Europe, Latin and North America, NHL risk was 
highest in men who have sex with men (MSM, aHR 1.30, 95% CI 1.14-1.48), followed 
by heterosexual men (referent), and women (aHR 0.66, 95% CI 0.57-0.78).  
Conclusions: The risk of developing NHL is higher in women in South Africa than in 
Europe and higher in MSM compared with heterosexual men and women. Reasons for 
these differences remain unclear. Early ART access and regular patient monitoring to 
avert low CD4 cell counts remain key for NHL prevention. 
Key words: Non-Hodgkin lymphoma; HIV; antiretroviral therapy; cohort study; 
incidence rates 
Introduction 
With the introduction of combination antiretroviral therapy (ART) the risk of 
developing human immunodeficiency virus (HIV)-related non-Hodgkin lymphoma 
(NHL) has substantially decreased [1–6]. However, NHL is still one of the most 
common cancers and a frequent cause of death among adults living with HIV [7–10]. 
The pathogenesis of HIV-related NHL is not well understood, but HIV-induced immune 
dysregulation and impaired control of oncogenic viruses seem to play an important role 
[11]. Epstein Barr virus (EBV), human herpesvirus 8 (HHV-8), and hepatitis C virus 
(HCV) have been recognized as causative agents of NHL, whereas the role of hepatitis 
B virus (HBV) in lymphomagenesis is being evaluated [12,13]. Prevalence and average 
age at acquisition of these viruses differ by population and geographic area. For 
example, EBV infection is typically delayed in high-income countries compared with 
low- and middle-income countries [12]. HHV-8 is highly prevalent in HIV-positive men 
who have sex with men (MSM) in most regions but is also common in heterosexual 
men and women in sub-Saharan Africa [14]. HCV prevalence is high in persons who 
inject drugs (PWID) [15], and it is increasing in MSM [16]. Furthermore, access to 
effective ART also varies across geographic regions. Median CD4 cell count at ART 
start is considerably lower in sub-Saharan Africa and Latin America than in Central 
Europe and North America [17]. Nevertheless, studies comparing the risk of developing 
NHL among adults living with HIV across different geographic regions are not 
available. We compared NHL incidence rates in adults who had started ART in the 
Asia-Pacific, South Africa, Europe, Latin America, or North America, and assessed 
factors associated with regional differences in NHL rates.  
Methods 
We analyzed cohort data from the International epidemiology Databases to Evaluate 
AIDS (IeDEA) and the Collaboration of Observational HIV Epidemiological Research 
in Europe (COHERE) in EuroCoord. For further information on data collection and 
merging, see Supplementary Box S1, http://links.lww.com/QAD/B367. We included 
adults (≥16 years old) living with HIV who started ART after cohort enrollment from 
1996 onwards. Incident NHL was defined as NHL diagnosed after ART start. Person-
years were measured from ART start to the first occurrence of NHL, last visit, death, or 
database closure. In a sensitivity analysis, we excluded NHL cases diagnosed within the 
first six months after ART start. We assumed that adults remained on ART throughout 
follow-up and did not consider treatment interruptions and terminations. We estimated 
NHL incidence rates in two different ways: i) by dividing the number of incident NHL 
cases by person-years (pys) at risk (referred to as raw incidence rates), and ii) using 
proportional hazard flexible parametric survival models [18]. Flexible parametric 
survival models allow estimating instantaneous NHL incidence rates at given time 
points and displaying the change in incidence rates over time graphically. Using these 
models, we estimated regional crude and adjusted NHL incidence rates over time after 
ART start and identified risk factors for NHL. We modeled the baseline hazard using 
restricted cubic splines with four degrees of freedom and allowed for time-dependent 
region effects with two degrees of freedom. We compared crude and adjusted NHL 
rates at 2 years after ART start across geographic regions and in a sensitivity analysis, 
we compared regional NHL rates at 5 years after ART start. We used likelihood ratio 
tests to test whether the effect of a risk factor on NHL risk differed across regions. We 
assessed sex, exposure group (MSM, heterosexual men, women), injection drug use 
(yes, no), age at ART start (continuous variable), first-line ART regimen (non-
nucleoside reverse transcriptase inhibitor [NNRTI]-based, protease inhibitor [PI]-based, 
other), calendar period of ART start (1996-1998, 1999-2003, 2004-2007, 2008-2014), 
and current (time-varying) CD4 cell count (continuous variable) in regression analyses. 
We used the last observation carried forward method for current CD4 cell count, i.e. we 
assumed that CD4 cell counts remained stable until a new measurement became 
available. CD4 cell count at ART start and HIV RNA load at ART start were assessed 
in descriptive analyses.  
We used models including region and only one additional covariate with or without its 
interaction with region (referred to as crude models) to compare the burden of incident 
NHL across regions. Adjusted models with relevant risk factors and their interaction 
with region (if necessary) were fit to assess remaining differences in regional NHL 
rates. Variable selection was not automated, but rather based on clinical and 
epidemiological reasoning as well as data availability and quality. We derived three 
adjusted models: model 1 included region, sex and its interaction with region, current 
CD4 cell count and its interaction with region, age at ART start, first-line ART regimen, 
and calendar period of ART start. Model 2 was restricted to regions with data on sexual 
orientation and PWID status (i.e. Europe, Latin and North America), and included 
region, age at ART start, current CD4 cell count, first-line ART regimen, calendar 
period of ART start, PWID status, and exposure group. To compare exposure group 
specific NHL rates across regions, we created model 3 by adding an interaction term 
between exposure group and region to model 2. To account for differences in HIV-
related risk factors across regions, we used the fitted models to predict NHL incidence 
rates for a chosen set of covariates (including region) and different time points. For men 
and women (model 1), we used the following covariate profile: start of an NNRTI-
based regimen between 2008-2014 at age 40 and current CD4 cell count of 450 cells/µl. 
For MSM, heterosexual men and women (model 3), we chose the following covariate 
profile: start of an NNRTI-based regimen between 2008-2014 at age 40, no injection 
drug use, and current CD4 cell count of 450 cells/µl. We present number and 
percentages of adults, medians with interquartile ranges (IQR), incidence rates per 
100,000 pys, and hazard ratios (HRs) with 95% confidence intervals (CI). All analyses 
were done in STATA 14 (Stata Corporation, USA), and R (R Foundation, Austria). 
Results 
Descriptive analyses 
We received data for 408,395 adults living with HIV enrolled in 49 eligible cohorts in 
the Asia-Pacific, Australia, Europe, South Africa, Latin and North America. We 
excluded 133,420 adults who did not start ART and another 64,077 adults for reasons 
detailed in Supplement Figure S1, http://links.lww.com/QAD/B367. We excluded five 
cohorts with <100 eligible adults and one region with <500 eligible adults (Australia). 
In a last step, we excluded 1,792 adults who did not have any CD4 cell count 
measurement. The Asia-Pacific region with 2,638 adults and 9 incident NHL cases was 
included for descriptive analyses but excluded from regression models.  
The descriptive dataset included 210,898 adults from the Asia-Pacific (n=2,638), South 
Africa (n=21,656), Latin America (n=8,569), North America (n=16,986) and Europe 
(n=161,049), see Table 1. Total follow-up was 1.1 million pys with a median of 4.1 
years per person (IQR 1.7-7.9); 1,552 adults developed NHL after starting ART (Europe 
1,225, North America 204, South Africa 63, Latin America 51, Asia-Pacific 9). Age at 
ART start was similar across regions with a median of 37.3 years (IQR 31.4-44.4). In 
the Asia-Pacific, Europe, North, and Latin America about 70% of adults were male, 
whereas in South Africa 63% were female. In Europe, Latin America, and North 
America, ≥40% of adults were MSM in contrast to 23% in the Asia-Pacific. Data on 
MSM and PWID were not available for South Africa. First-line ART regimens differed 
by region, with NNRTI used by ≥90% of adults in South Africa and the Asia-Pacific, 
and about 40% in Europe and North America. Median CD4 cell count at ART start was 
highest in Europe (250, IQR 126-368) and lowest in South Africa (107 cells/µL, IQR 
43-176). While in South Africa and the Asia-Pacific >95% of adults started ART after
2003, 39% of the European and 63% of the North American study population had 
started ART before 2004 (Table 1).  
In adults who developed NHL, median time from ART start to NHL diagnosis was 1.1 
years (IQR 0.3-3.6), see Supplementary Table S1, http://links.lww.com/QAD/B367. 
Fifty-seven (4%) adults diagnosed with incident NHL had a history of Kaposi sarcoma 
(KS); 39 of them (68%) were MSM. Median CD4 cell count at NHL diagnosis was 220 
cells/µL (IQR 96-379); median age at NHL diagnosis was 42.8 years (IQR 36.6-50.6). 
The raw overall NHL incidence rate was 142/100,000 pys (95% CI 135-150). Raw NHL 
incidence rates per 100,000 pys were similar in Europe (137, 95% CI 130-145), South 
Africa (116, 95% CI 91-149), Asia-Pacific (116, 95% CI 60-223), and Latin America 
(112, 95% CI 85-147), but higher in North America (225, 95% 196-258), see 
Supplementary Table S2, http://links.lww.com/QAD/B367. Incidence rates were 
particularly high (>1,000/100,000 pys) in adults with current CD4 cell counts <50 
cells/µL in North America and Europe (Supplementary Table S3, 
http://links.lww.com/QAD/B367). In contrast, in South Africa, NHL incidence rates 
were relatively low (150/100,000 pys) in adults with CD4 cell counts <50 cells/µL. 
NHL risk factors 
In all regions (model 1), NHL incidence rates were highest immediately after starting 
ART and decreased thereafter (Figure 1), but the decrease was less pronounced in 
South Africa. The effect of sex on the risk of developing NHL differed across regions 
(p-value for interaction=0.016). Based on both crude and adjusted analyses, NHL rates 
were higher among men than among women in Europe, Latin, and North America 
(Table 2). In South Africa, the risk of developing NHL was similar in women and men 
(aHR 1.13, 95% CI 0.67-1.91, referent: men).  
The effect of current CD4 cell counts on the risk of developing NHL also varied by 
region (model 1, p=0.004). In Europe, Latin and North America, NHL rates decreased 
with increasing current CD4 cell counts (Table 2). Per 100 cells/µl increase, NHL rates 
declined by about one-third in Latin America (aHR 0.66, 95% CI 0.55-0.80), North 
America (aHR 0.65, 95% CI 0.60-0.71) and Europe (aHR 0.72, 95% CI 0.69-0.74). In 
contrast, no clear association between current CD4 cell count and the risk of developing 
NHL was found in South Africa (aHR 0.92, 95% CI 0.78-1.08). The effect of age at 
ART start, calendar period of ART start, and first-line regimen did not differ across 
regions (model 1, Supplementary Table S4, http://links.lww.com/QAD/B367). In all 
regions, NHL rates increased with age (per 10-year increase, aHR 1.29, 95% CI 1.23-
1.35). NHL rates decreased from the period 1996-1998 to 1999-2003 and remained 
stable thereafter. There was no evidence for an association between first-line ART 
regimen and the risk of developing NHL.  
In model 2 without South Africa, we explored the effect of exposure group and injection 
drug use on NHL risk (Table 3, Supplementary Figure S2, 
http://links.lww.com/QAD/B367). In adjusted analyses, MSM had the highest NHL 
rates, followed by heterosexual men and women. Compared with heterosexual men, the 
risk of developing NHL was 30% higher among MSM (aHR 1.30, 95% CI 1.14-1.48), 
and it was 34% lower in women (aHR 0.66, 95% CI 0.57-0.78). The effect of exposure 
group on the risk of developing NHL did not differ across Europe, North and Latin 
America (p=0.330). NHL rates were similar in PWID compared with persons who did 
not inject drugs in crude (HR 0.98; 95% CI 0.84-1.16) and adjusted analyses (aHR 0.94, 
95% CI 0.79-1.12). The effect of injection drug use on NHL rates did not vary by region 
(p=0.121).  
Comparison of NHL rates across geographic regions 
The risk of developing NHL was higher in South African women than in European 
women (aHR 1.79, 95% CI 1.19-2.70, at 2 years after starting ART). In male adults, 
NHL rates were similar in South Africa and Europe. In crude analyses excluding South 
Africa, NHL rates at 2 years after ART start were higher in North America than in 
Europe across all exposure groups, see Table 4. However, after adjustment for HIV-
related risk factors – in particular current CD4 cell count – NHL rates among North 
American women (aHR 0.97, 95% CI 0.64-1.49), heterosexual men (aHR 1.26, 95% CI 
0.92-1.74) and MSM (aHR 1.20, 95% CI 0.96-1.49) became more comparable to their 
European counterparts’ rates. In Latin American women, NHL rates at 2 years after 
starting ART were lower than in European women (aHR 0.26, 95% CI 0.09-0.77). Of 
note, this estimate was based on only four incident NHL cases in Latin American 
women. Among heterosexual men (aHR 0.72, 95% CI 0.41-1.27) and MSM (aHR 0.84, 
95% CI 0.55-1.27) in Latin America, NHL rates were similar to their European 
counterparts’ rates.  
Sensitivity analyses 
When we excluded NHL cases diagnosed within the first six months after ART start in 
sensitivity analyses, raw NHL incidence rates decreased (raw overall NHL incidence 
rate: 100/100,000 pys, 95% CI 94-106, Supplementary Table S5, 
http://links.lww.com/QAD/B367), but the risk factor analyses (Supplementary Tables 
S6 and S7, http://links.lww.com/QAD/B367) and the regional comparison of NHL rates 
(Supplementary Table S8, http://links.lww.com/QAD/B367) remained similar. When 
comparing NHL rates at 5 years (instead of 2 years) after ART start, the regional NHL 
incidence pattern did not change much. Women in South Africa still had considerably 
higher NHL rates than European women (aHR 2.30, 95% CI 1.34-3.95). After 
adjustment for HIV-related risk factors, NHL rates in all population groups in North 
America became more similar to their European counterparts’ rates, but they remained 
elevated (Supplementary Table S9, http://links.lww.com/QAD/B367). 
Discussion 
The overall NHL incidence rate in adults who had started ART was 142/100,000 pys. 
This exceeds the NHL incidence rates of up to 10/100,000 pys reported for a 
comparable age group (40-44 years) from the general population in the regions included 
in our analysis [19]. After adjustment for HIV-related risk factors, NHL rates after 
starting ART were similar among men in all regions. In contrast, NHL rates were higher 
in South African than in European women. Across Europe, Latin and North America, 
the risk of developing NHL was highest in MSM, followed by heterosexual men, and 
women. In South Africa, NHL rates were similar in men and women. With increasing 
current CD4 cell counts, the risk of developing NHL decreased among adults in Europe, 
Latin and North America. However, we did not find an association between current 
CD4 cell count and the risk of developing NHL in South African adults. 
Our analysis is based on a large dataset of adults living with HIV in five continents who 
had started ART, and it is the first analysis providing a direct comparison of NHL rates 
in adults living with HIV across geographic regions. We restricted our analysis to adults 
who had started ART without prior NHL, and we adjusted for current CD4 cell count to 
account for regional differences in ART provision. The age structures of the included 
adult populations were similar across regions. We accounted for remaining differences 
by including age at ART start in the adjusted models. However, NHL ascertainment was 
not standardized across regions with some cohorts using record linkages with cancer 
registries and others reviewing medical charts and pathology reports to complement 
their routine data collection. Variation in the completeness of NHL ascertainment across 
regions might, therefore, have contributed to regional differences in NHL rates. 
Information on NHL subtypes was unavailable for most regions and subtype-specific 
analyses were not possible. However, without standardized protocols for 
histopathological assessments of NHL across regions, subtype-specific analyses might 
also be of limited value. For South Africa, reliable cancer data were only available for 
two urban cohorts that had improved their cancer case recording through record 
linkages with the National Cancer Registry [20]. These data might not be representative 
for rural areas of South Africa and for other countries in the Southern African region. 
We did not take into account ART interruptions and terminations, and not all included 
adults who had started ART will have remained on ART. Therefore, our NHL incidence 
rate estimates are not necessarily representative for adults who stayed on ART 
continuously. HIV RNA data were largely missing in some regions and could not be 
used to assess ART effectiveness. Data on MSM and PWID were not available for 
South Africa, but in this region, HIV is mainly spread through heterosexual and vertical 
transmission. Comprehensive data on ethnicity or region of origin were only available 
for North America or Europe, respectively, and could not be included in our 
multiregional analyses. Information on other NHL risk factors including time from HIV 
infection to ART start and sero-status for potentially relevant co-infections such as 
EBV, HBV, HCV, and HHV-8 were also mostly missing. 
Our study confirms that adults who have started ART remain at considerable risk of 
developing NHL. The overall incidence rate was 142/100,000 pys which is comparable 
to incidence rates reported from participating [1,2,4,20–22] and other study groups 
[5,23–25]. We and others have shown that NHL incidence rates are highest within the 
first six months after starting ART [1], which might be explained by more frequent 
NHL diagnoses in this time window due to a closer examination of adults at ART start. 
Other studies have suggested that immune reconstitution inflammatory syndrome may 
contribute to the increased number of NHL cases in the first months of ART [26,27]. 
Our study showed that in most regions men had higher NHL rates than women, which is 
line with findings from the general population [19] and previous studies in HIV-positive 
populations [1,2,22,28]. In our study, NHL rates in South Africa were about the same in 
men and women. Previous studies in this region had not assessed the effect of sex on the 
risk of developing NHL [20,29]. Across all regions where data on exposure group were 
available, MSM were at highest risk of developing NHL followed by heterosexual men 
and women. Similar differences in NHL rates by exposure group have been described 
before in the Swiss HIV Cohort Study [30], the French Hospital Database on HIV [22] 
and the COHERE in EuroCoord collaboration [2] – data sources also included in the 
current analysis. We and others [1,2,22,30] did not observe increased NHL rates in 
PWID. In line with previous studies, we found that across all regions NHL rates 
increased with age [1,2,22,28] and declined over calendar periods [1,3–6,31]. As 
previously reported [2,22,26,28,30,32,33,34], we also observed that in most regions the 
risk of developing NHL decreased with increasing CD4 cell counts. The lack of an 
association between current CD4 cell count and NHL rates in South Africa was mainly 
driven by a small number of NHL cases among adults with low CD4 cell counts in that 
region. This might be due to selection and detection biases. In settings with limited 
resources, adults with very low CD4 cell counts might die before an NHL diagnosis can 
be made. In addition, NHL often presents with non-specific symptoms such as weight 
loss and night sweats, which might be misdiagnosed as tuberculosis, especially in 
regions where tuberculosis prevalence is high [35,36].  
HIV-associated immunosuppression and co-infection with oncogenic viruses play an 
important role in the pathogenesis of HIV-related NHL [11]. Early access to HIV care 
and maintenance of high CD4 cell counts are, therefore, key measures to lower the risk 
of developing NHL [22,23,37]. In our study, population group specific NHL rates were 
mostly similar across geographic regions when taking into account differences in HIV-
related risk factors in these populations. For example, in crude analyses, NHL rates in 
all population groups were higher in North America than in Europe, but the rates 
became similar when we adjusted for age at ART start, first-line regimen, calendar 
period of ART start, and in particular current CD4 cell counts. However, also in 
adjusted analyses, MSM had higher NHL rates than heterosexual men and women 
living with HIV. Furthermore, South African women had a higher risk of developing 
NHL than European women. It remains unclear why the risk of developing NHL is 
elevated among those population groups. More frequent clinical assessment in MSM 
compared with other population groups could lead to a detection bias of NHL in MSM. 
However, a previous study observed the association between MSM and higher cancer 
risk specifically for NHL, KS, and anal cancer, but not for other cancers [22]. Co-
infection patterns might also contribute to the increased NHL rates in MSM and South 
African women. Both South African women and MSM are at high risk of co-infection 
with HHV-8 [14], which has been associated with an increased NHL risk. Yet, HHV-8 
has only been associated with two NHL subtypes, i.e. primary effusion lymphoma 
(PEL) and HHV-8-associated diffuse large B-cell lymphoma, a form of multicentric 
Castleman’s disease [38], and these NHL subtypes are rare entities. For example, PEL 
represents <5% of all NHLs in HIV-positive populations [39,40]. Therefore, these 
HHV-8-related NHL subtypes are unlikely to fully explain the increased NHL risk 
observed among MSM and South African women. HCV has been associated with NHL 
development [12,13], and its prevalence is increasing in MSM [16], but we did not find 
increased NHL rates among PWID, the population group at highest risk for HCV co-
infection. The role of co-infections in lymphomagenesis is complex and incompletely 
understood. Dedicated studies including information on co-infection status of adults 
living with HIV are needed to clarify whether the increased NHL risk we observed 
among MSM and South African women can be explained by underlying co-infection 
patterns. 
Conclusion 
A better understanding of lymphomagenesis and associated etiologic factors is needed 
to eventually be able to develop specific preventive measures against NHL in adults 
living with HIV. In the meantime, early access to ART and regular patient monitoring 
to avert low current CD4 cell counts remain key for NHL prevention.  
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Table 1: Patient characteristics at start of ART, stratified by region. 
Asia-
Pacific 
South Africa Latin 
America 
North 
America 
Europe 
N (%) N (%) N (%) N (%) N (%) 
All adults 2,638 
(100%) 
21,656 
(100%) 
8,569 
(100%) 
16,986 
(100%) 
161,049 
(100%) 
Median 
follow-up 
time (IQR) 
[years] 
2.7 (1.7-
3.9) 
2.0 (0.8-4.0) 4.7 (2.0-
8.2) 
4.3 (1.7-8.5) 4.5 (1.9-8.5)
Sex / exposure 
group 
 Women 814 (31%) 13,667 (63%) 2,267 
(26%) 
4,203 (25%) 44,180 
(27%) 
 Men 1,824 
(69%) 
7,989 (37%) 6,302 
(74%) 
12,783 
(75%) 
116,869 
(73%) 
Heterosexual 
1,200 
(45%) 
6,776 (31%) 1,927 
(22%)
3,285 (19%) 45,110 
(28%)
    MSM 616 (23%)  NR 3,637 
(42%) 
8,692 (51%) 64,232 
(40%) 
 Missing 8 (<1%) 1,213 (6%) 738 (9%) 806 (5%) 7,527 (5%) 
PWID 
 Yes 172 (7%) NR 170 (2%) 2,174 (13%) 17,755 
(11%) 
 No 2,458 
(93%) 
NR  8,348 
(97%) 
14,812 
(87%) 
143,294 
(89%) 
 Missing 8 (<1%)  21,656 
(100%) 
 51 (1%) 0 (0%) 0 (0%) 
Median age at 
ART start 
(IQR) [years] 
36.3 
(30.5-43.0) 
36.4 
(31.0-42.7) 
35.6 
(29.7-
42.9) 
39.6 
(33.8-46.1) 
37.3 
(31.4-44.5) 
Age at ART 
start [years] 
16-25 232 (9%) 1,737 (8%) 1,008 
(12%) 
927 (5%) 13,262 (8%)
26-35 1,055 
(40%) 
8,643 (40%) 3,426 
(40%) 
4,838 (28%) 57,975 
(36%) 
36-45 867 (33%) 7,777 (36%) 2,609 
(30%) 
6,945 (41%) 55,577 
(35%) 
46-55 354 (13%) 2,883 (13%) 1,114 
(13%) 
3,345 (20%) 23,879 
(15%) 
 ≥56 130 (5%) 616 (3%) 412 (5%) 931 (5%) 10,356 (6%)
First line 
treatment 
 NNRTI-based 2,366 
(90%) 
20,492 (95%) 6,407 
(75%) 
6,200 (37%) 67,059 
(42%) 
 PI-based 235 (9%) 1,117 (5%) 1,959 
(23%) 
9,231 (54%) 82,614 
(51%) 
 Other ART 37 (1%) 47 (<1%) 203 (2%) 1,555 (9%) 11,376 (7%)
Calendar year 
of ART start 
 1996-1998 0 (0%) 0 (0%) 109 (1%) 5,466 (32%) 19,216 
(12%) 
 1999-2003 100 (4%) 99 (<1%) 1,969 
(23%) 
5,228 (31%) 43,675 
(27%) 
 2004-2007 513 (19%) 10,479 (48%) 2,811 
(33%) 
4,091 (24%) 39,881 
(25%) 
 2008-2014 2,025 
(77%) 
11,078 (51%) 3,680 
(43%) 
2,201 (13%) 58,277 
(36%) 
Median CD4 
cell count at 
ART start 
(IQR) 
[cells/µl] 
138 
(43-234) 
107 
(43-176) 
165 
(61-273) 
233 
(92-378) 
250 
(126-368) 
 CD4 cell 
count at ART 
start (IQR) 
[cells/µl] 
 <50 677 (26%) 5,507 (25%) 1,527 
(18%) 
2,652 (16%) 18,051 
(11%) 
50-99 327 (12%) 3,940 (18%) 1,035 
(12%) 
1,319 (8%) 11,903 (7%)
100-199 603 (23%) 7,242 (33%) 1,658 
(19%) 
2,631 (15%) 26,061 
(16%) 
200-349 735 (28%) 2,626 (12%) 2,151 
(25%) 
4,205 (25%) 48,356 
(30%) 
350-499 96 (4%) 398 (2%) 589 (7%) 2,348 (14%) 23,977 
(15%) 
500-699 16 (1%) 185 (1%) 205 (2%) 1,344 (8%) 11,253 (7%)
≥700 6 (<1%) 82 (<1%) 81 (1%) 694 (4%) 5,510 (3%) 
Missing 178 (7%) 1,676 (8%) 1,323 
(15%) 
1,793 (11%) 15,938 
(10%) 
Median HIV 
RNA at ART 
start (IQR) 
[log10 
copies/ml] 
5.0 
(4.5-5.4) 
4.5 
(2.7-5.3) 
4.9 
(4.3-5.4) 
4.5 
(3.5-5.2) 
4.8 
(4.1-5.3) 
HIV RNA at 
ART start 
(IQR) [log10 
copies/ml] 
 <2.7 44 (2%) 1,202 (6%) 285 (3%) 2,537 (15%) 13,187 (8%)
 2.7-3.9 200 (8%) 596 (3%) 704 (8%) 2,417 (14%) 18,431 
(11%) 
 4.0-4.9 760 (29%) 1,319 (6%) 2,293 
(27%) 
5,183 (31%) 51,333 
(32%) 
 5.0-5.9 961 (36%) 1,379 (6%) 2,484 
(29%) 
4,442 (26%) 50,451 
(31%) 
 ≥6.0 78 (3%) 278 (1%) 239 (3%) 122 (1%) 5,078 (3%) 
 Missing 595 (23%) 16,882 (78%) 2,564 
(30%) 
2,285 (13%) 22,569 
(14%) 
ART, antiretroviral therapy; IQR, interquartile range; MSM, men who have sex with 
men; NNRTI, non-nucleoside reverse-transcriptase inhibitor; NR, not reported; PI, 
protease-inhibitor; PWID, people who inject drugs; RNA, ribonucleic acid.
Table 2: Crude and adjusted hazard ratios for the regional effect of sex and current CD4 cell count on the risk of developing NHL in adults who 
started ART. 
South Africa Latin America North America Europe 
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
Sex 
Men 1.00 1.00 1.00 1.00
 Women (crude) 1.00 (0.60 - 1.69) 0.23 (0.08 - 0.64) 0.52 (0.36 - 0.75) 0.54 (0.47 - 0.63) 
 Women (adjusted*) 1.13 (0.67 - 1.91) 0.24 (0.09 - 0.67) 0.52 (0.36 - 0.76) 0.59 (0.51 - 0.69) 
Current CD4 cell count 
Per 100 cells/µl increase (crude) 0.91 (0.77 - 1.07) 0.66 (0.54 - 0.80) 0.66 (0.61 - 0.71) 0.71 (0.69 - 0.73) 
Per 100 cells/µl increase 
(adjusted**) 
0.92 (0.78 - 1.08) 0.66 (0.55 - 0.80) 0.65 (0.60 - 0.71) 0.72 (0.69 - 0.74) 
* Adjusted for age at ART start, calendar year of ART start, first-line ART regimen, current CD4 cell count and its interaction with region
(model 1).
** Adjusted for age at ART start, calendar year of ART start, first-line ART regimen, sex and its interaction with region (model 1). 
ART, antiretroviral therapy; CI, confidence interval; HR, hazard ratio; NHL, non-Hodgkin lymphoma. 
Table 3: Crude and adjusted hazard ratios for the effect of exposure group and drug use on 
the risk  of developing NHL in adults who started ART, restricted to North America, Latin 
America, and Europe. 
Crude Adjusted*
HR (95% CI) HR (95% CI) 
Exposure group 
 Women 0.52 (0.44 - 0.61) 0.66 (0.57 - 0.78) 
 Heterosexual men 1.00 1.00 
 MSM 0.95 (0.84 - 1.07) 1.30 (1.14 - 1.48) 
PWID 
 No 1.00 1.00 
 Yes 0.98 (0.84 - 1.16) 0.94 (0.79 - 1.12) 
*Adjusted for age, calendar year of ART start, first-line ART regimen, current CD4 cell
count, and exposure group or PWID, respectively (model 2) 
ART, antiretroviral therapy; CI, confidence interval; HR, hazard ratio; MSM, men who have 
sex with men; NHL, non-Hodgkin lymphoma; PWID, people who inject drugs.
Table 4: Comparison of NHL rates between different regions and Europe: Crude and adjusted HRs for being diagnosed with 
NHL at 2 years after ART start in different population groups. 
Women1 All men1 Heterosexual men2 MSM2
Crude HR  
(95% CI) 
Adjusted 
HR*  (95% 
C )
Crude HR 
(95% CI) 
Adjusted 
HR*  (95% 
C )
Crude 
HR  
(9 % C )
Adjusted 
HR**  (95% 
C )
Crude 
HR  
(9 % C )
Adjusted 
HR**  (95% 
C )Region        
   Europe 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   North 
America 
1.66  
(1.14 - 2.41) 
0.97 
(0.64 - 1.49) 
1.74  
(1.45 - 
2 08)
1.10  
(0.85-1.43) 
1.74  
(1.26-
2 40)
1.26  
(0.92-1.74) 
1.72  
(1.38-
2 14)
1.20  
(0.96-1.49) 
   Latin 
America 
0.36  
(0.13 - 0.98) 
0.26  
(0.09 - 0.77) 
0.84  
(0.59 - 
0.64  
(0.38 - 1.09) 
0.80  
(0.45-
0.72  
(0.41-1.27) 
1.03  
(0.68-
0.84  
(0.55-1.27) 
   South Africa 1.48  
(1.03 - 2.14) 
1.79  
(1.19 – 2.70)
0.80  
(0.51 - 
0.94  
(0.56 – 1.58)
- - - - 
1 From models including the variable “sex” and its interaction with region. 
2 From models including the variable “exposure group” and its interaction with region. 
* Adjusted for age at ART start, calendar period of ART start, first-line ART regimen, current CD4 cell count and its interaction with 
region, and sex and its interaction with region (model 1).
** Adjusted for age at ART start, calendar period of ART start, first-line ART regimen, current CD4 cell count, drug use, and 
exposure group and its interaction with region (model 3).
ART, antiretroviral therapy; CI, confidence interval; HR, hazard ratio; NHL, non-Hodgkin lymphoma.
